Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 10/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488185 | 0.87 | TRPA1 (0.53) | TRPA1MAPTRXFP1LMNAPOLB | |
| SCHEMBL6814150 | 0.81 | TRPA1 (0.51) | TRPA1MAPT | |
| SCHEMBL6476858 | 0.81 | TRPA1 (0.49) | TRPA1MAPTPTGER4 | |
| SCHEMBL6292190 | 0.80 | MAPT (0.45) | TRPA1MAPTRXFP1 | |
| SCHEMBL6288742 | 0.78 | MAPT (0.49) | TRPA1MAPT | |
| SCHEMBL5957337 | 0.77 | TRPA1 (0.81) | TRPA1 | |
| SCHEMBL6818666 | 0.77 | TRPA1 (0.44) | TRPA1MAPTRXFP1LMNAPOLB | |
| SCHEMBL6818671 | 0.75 | TRPA1 (0.42) | TRPA1MAPTRXFP1LMNAPOLB | |
| SCHEMBL6484781 | 0.75 | PTGER4 (0.41) | MAPTRXFP1PTGER4LMNAPOLB | |
| SCHEMBL6484094 | 0.75 | LMNA (0.42) | TRPA1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004014908-A1 | HETEROBICYLCIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | claimed |
| US-6897223-B2 | Pyridine fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014908-A1 | HETEROBICYLCIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039012-A1 | Pyridine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | TRPA1 4030/4885MAPT 4485/4885RXFP1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.